



+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

A circular ink stamp from the U.S. Patent & Trademark Office. The text "U.S. PATENT & TRADEMARK OFFICE" is arranged in a circle around the date "APR 27 1961". The stamp is partially obscured by a vertical line and some other markings.

Complete if Known

Application Number	09/577,264
Filing Date	05/22/2000
First Named Inventor	John S. Pat
Group Art Unit	1654
Examiner Name	Unassigned
Attorney Docket Number	0002.12

RECEIVED

~~MAY 01~~ 2001

~~TECH CENTER~~ 1600/2900

Sheet 1 of 1

[illegible][illegible]

David L. Lyon

12-7-05

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box

+

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/577,264
Filing Date	05/22/2000
First Named Inventor	John S. Patton
Group Art Unit	1654
Examiner Name	Unassigned
Attorney Docket Number	0002.12

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DL		Neer et al. (1987) Osteoporosis 53:829-835
		Hesch et al. (1988) Calcif. Tissue Int. 42:341-344
		Habener et al. (1971) Proc. Natl. Acad. Sci. USA 68:2986-2991
		Patton et al. (1992) Adv. Drug Delivery Reviews 8:179-196
DL		Harms et al. (1987) Int. Symp. On Osteoporosis, Aalborg, Abstr. 232:723-724
DL		Patton (1994) J. Controlled Release 28: 79-85
DL		Abstract of Japanese Patent, Document Number JP 02 000111, Date 01/05/90
X		Patton (1998) Modern Drug Discovery, 19-28

Examiner
Signature

David Patton

Date
Considered

12-7-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/577,264
Filing Date	05/22/2000
First Named Inventor	John S. Patton
Group Art Unit	1654
Examiner Name	Unassigned
Attorney Docket Number	0002.12


Sheet 1 of 1

[illegible]

12-7-05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	09/577,264
Filing Date	05/22/2000
First Named Inventor	John S. Patton
Art Unit	1853
Examiner Name	Unassigned
Attorney Docket Number	0002.12

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


[illegible]

Examiner Signature	David Jackson	Date Considered	12-7-05
-----------------------	---------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/577,264
Filing Date	05/22/2000
First Named Inventor	John S. Patton
Art Unit	1653
Examiner Name	Unknown
Attorney Docket Number	0002.12

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DL	AA	HODSMAN ET AL., "Biochemical Responses to Sequential Human Parathyroid Hormone (1-38) and Calcitonin in Osteoporotic Patients," Bone and Mineral (1990), Vol. 9, p. 137-152.	
DL	AB	HODSMAN ET AL., "Bone Densitometric and Histomorphometric Responses to Sequential Human Parathyroid Hormone (1-38) and Salmon Calcitonin in Osteoporotic Patients," Bone and Mineral (1991), Vol. 14, p. 67-83.	
DL	AC	BEAUCAGE ET AL., "Deoxynucleoside Phosphoramidites - A New Class of Key Intermediates for Deoxypolynucleotide Synthesis," Tetrahedron Letters (1981), Vol. 22(2), p. 1859-1862.	
DL	AD	HESCH ET AL., "First Clinical Observations with hPTH(1-38), a More Potent Human Parathyroid Hormone Peptide," Horm. Metabol. Res. (1984), Vol. 16, p. 559-560.	

Examiner Signature	David Patton	Date Considered	12-7-05
--------------------	--------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

RECEIVED

MAR 14 2005
TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → **[+]**

PTO/SB/088 (10-88)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/577,264
Filing Date	05/22/2000
First Named Inventor	John S. Patton
Group Art Unit	1654
Examiner Name	Unassigned
Attorney Docket Number	0002.12

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DK		Neer et al. (1987) Osteoporosis 53:829-835	✓
		Hesch et al. (1988) Calcif. Tissue Int. 42:341-344	✓
		Habener et al. (1971) Proc. Natl. Acad. Sci. USA 68:2986-2991	✓
		Patton et al. (1992) Adv. Drug Delivery Reviews 8:179-196	✓
		Harms et al. (1987) Int. Symp. On Osteoporosis, Aalborg, Abstr. 232:723-724	✓
DK		Patton (1994) J. Controlled Release 28: 79-85	✓
DK		Abstract of Japanese Patent, Document Number JP 02 000111, Date 01/05/90	✓
X		Patton (1998) Modern Drug Discovery, 19-28	

Examiner
Signature

David L. Patton

Date
Considered

12-7-05

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.